LUPIN

Forecasts Strong EBITDA Margins and Tax Rate for FY25

Lupin, a pharmaceutical company, has provided guidance on its financial outlook during a conference call. The company expects to achieve EBITDA margins between 23% and 23.5% in the fiscal year 2025. Additionally, Lupin anticipates an effective tax rate (ETR) of approximately 20% to 21% for the full year.